Recent Finacing
Recent Raise
Inipharm develops small-molecule therapies targeting HSD17B13 to mimic protective variants, mitigate liver inflammation and fibrosis, and advance its lead program with CRO Jubilant Biosys toward IND and clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Inipharm.
